Award

Sander lauded for his efforts
to bring science to all

He won ASBMB's DeLano computational science award
Isha Dey
April 1, 2018

Chris Sander, director of the cBio Center at the Dana–Farber Cancer Institute and a professor of cell biology at Harvard Medical School, is the 2018 recipient of the American Society for Biochemistry and Molecular Biology’s DeLano Award for Computational Biosciences.

Sander is recognized internationally in the field of computational and systems biology. He is credited with integrating computational sciences into biological research to make scientific resources easily accessible to the public. One example is the cBioPortal for Cancer Genomics, developed with colleagues Ethan Cerami and Nikolaus Schulz in his group during his time at the Memorial Sloan–Kettering Cancer Center. It is now an international open-source project containing cancer genomics data sets from published studies and data generated by The Cancer Genome Atlas and other sources.

Chris-Sander-web.jpg

“I subscribe to Warren DeLano’s mission statement: ‘Lack of access to effective software continues to be a major hindrance to scientific progress and therapeutic discovery. For the benefit of all society, we need to pursue new and complementary approaches to the creation and dissemination of scientific software.’ I am grateful we can make scientific software available to the world.”

— Chris Sander

As Joan Massagué, director of the Sloan–Kettering Institute and a leading scientist in cancer metastasis, pointed out in his nomination, Sander and his group have developed many online resources that unify scientists from different fields. Examples include the Dictionary of Secondary Structure of Proteins, co-developed with Wolfgang Kabsch at a Max Planck Institute and in widespread use for 35 years; the miRanda microRNA target prediction algorithm, with colleague Debora Marks; and the BioPAX and Pathway Commons resources for sharing biological pathway data, with former postdoctoral fellows Emek Demir and Gary Bader. In 2010, Sander and Marks developed Evfold, a method adapted from statistical physics that predicts protein 3-D structure folds from genetic sequences by analysis of evolutionary covariation patterns. Sander’s work “has contributed to key advancements in computational biology, structural biology, cancer genomics and cancer systems biology,” Massagué wrote.

Sander was trained in physics and mathematics at the University of Berlin, the University of California, Berkeley, and the Niels Bohr Institute in Denmark, and he earned his Ph.D. in theoretical physics from the State University of New York at Stony Brook. He founded the biocomputing program at the European Molecular Biology Laboratory and, with Michael Ashburner, co-founded the research section of the European Bioinformatics Institute. After working as scientific founder at a biotech startup, Millennium Information, he established the Department of Computational Biology at Memorial Sloan–Kettering.

Sander has co-authored more than 400 publications. He has a patent,“Models for combinatorial perturbations of living biological systems,” and has served on scientific advisory boards for organizations worldwide and helped shape many research programs. The International Society for Computational Biology awarded him its 2010 Accomplishment by a Senior Scientist Award.

The DeLano award recognizes the use of computational tools in biological research and providing public access to those tools. Sander is the ideal candidate, Massagué wrote in his nomination letter. Following the legacy of Warren DeLano, who advocated open-source practices in the sciences, Sander not only “built highly productive bridges between the computational and biological sciences through interdisciplinary and translational collaborations” but also “always ensured that resources developed by his team, as well as experimental data, are freely available to the public,” Massagué wrote.

Sander will receive his award during the 2018 ASBMB Annual Meeting in San Diego. His lecture, “Solutions to the computational protein folding problem,” will take place at 9 a.m. April 23 in Room 6B at the San Diego Convention Center.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Isha Dey

Isha Dey is a scientist at Thermo Fisher Scientific.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in People

People highlights or most popular articles

How undergrad research catalyzes scientific careers
Essay

How undergrad research catalyzes scientific careers

Aug. 27, 2025

Undergraduate research doesn’t just teach lab skills, it transforms scientists. For Antonio Rivera and Julissa Cruz–Bautista, joining a lab became a turning point, fostering critical thinking, persistence and research identity.

Simcox and Gisriel receive mentoring award
Member News

Simcox and Gisriel receive mentoring award

Aug. 25, 2025

They were honored for contributing their time, knowledge, energy and enthusiasm to mentoring postdocs in their labs.

ASBMB names 2025 Marion B. Sewer scholarship recipients
Society News

ASBMB names 2025 Marion B. Sewer scholarship recipients

Aug. 21, 2025

Ten undergraduates interested in biochemistry and molecular biology will each receive $2,000 toward their tuition and related educational costs.

Attie named honorary professor
Member News

Attie named honorary professor

Aug. 18, 2025

This award includes $100,000 of research funding and recognizes faculty who have made major contributions to the advancement of knowledge through their research, teaching and service activities.

Meet the 2025 SOC grant awardees
Outreach

Meet the 2025 SOC grant awardees

Aug. 15, 2025

Five science outreach and communication projects received up to $1,000 from ASBMB to promote the understanding of molecular life science.

Unraveling cancer’s spaghetti proteins
Profile

Unraveling cancer’s spaghetti proteins

Aug. 13, 2025

MOSAIC scholar Katie Dunleavy investigates how Aurora kinase A shields oncogene c-MYC from degradation, using cutting-edge techniques to uncover new strategies targeting “undruggable” molecules.